Trulieve Reports Second Quarter 2026 Results
Trulieve Cannabis Corp. (NYSE: TRLV) reported Q2 2026 revenue of $271 million and 60% gross margin, with 94% of revenue from retail sales. GAAP net loss attributable to common shareholders was $406 million, including a $407 million impact from Harvest deconsolidation. Adjusted net income was $20 million. Cash flow from operations was $109 million and free cash flow $74 million for the first half. The company also announced a share repurchase program.
How this was made
The 30-second read
Why it matters
The release combines financial performance (revenue, gross margin, adjusted EBITDA, free cash flow), balance sheet liquidity (cash at quarter end), corporate actions (buyback), and regulatory/operational milestones (DEA registration filings, NYSE listing, state expansion).
Market read
This is a primary earnings release with multiple tradable datapoints: adjusted profitability, cash generation, buyback authorization, and regulatory progress tied to Schedule III rescheduling.
What to watch
Traders may underweight the operational detail (pharmacy shipments, dispensary count, cultivation capacity) relative to the accounting effects; also, the buyback authorization size ($50M cap) may be modest versus market expectations.
Background
Trulieve is a US medical cannabis operator reporting Q2 2026 results, including the effects of Harvest deconsolidation and ongoing regulatory steps after federal rescheduling to Schedule III.
Ticker impact
Trulieve reported Q2 2026 revenue of $271M, 60% gross margin, and a large GAAP net loss tied to Harvest deconsolidation, plus a $50M buyback authorization.
Likely choppy reaction: adjusted EBITDA and free cash flow support, but the GAAP loss magnitude and Harvest deconsolidation accounting may temper enthusiasm.
The release provides multiple decision-relevant datapoints (revenue, gross margin, adjusted EBITDA, FCF, cash balance, buyback size, and DEA registration filings). However, it does not provide forward guidance or consensus context, limiting conviction on direction and magnitude.
Market effects
US medical cannabis names may see read-through from DEA Schedule III-related registration filings and NYSE listing following rescheduling.
Georgia pharmacy shipments and Florida dispensary openings highlight continued state-level expansion execution.
Limited direct global impact, but the DEA Schedule III framing can influence broader US regulatory expectations for the sector.
Counterpoint
Adjusted results and cash flow may look solid, but the GAAP loss and Harvest deconsolidation suggest underlying earnings quality and consolidation structure are still in flux.
Key entities
- companyTrulieve Cannabis Corp.
Reported Q2 2026 results, including adjusted EBITDA and free cash flow, and disclosed DEA registration filings and a share repurchase authorization.
- companyHarvest
Its deconsolidation on June 3, 2026 drove a large portion of the GAAP net loss reported for the quarter.
- regulatorDrug Enforcement Administration (DEA)
Trulieve filed applications to register state licensed medical marijuana operations following rescheduling to Schedule III.